

1 **Wastewater Surveillance of SARS-CoV-2 across 40 U.S. states**

2

3 Fuqing Wu(1,2)†; Amy Xiao(1,2)†; Jianbo Zhang(1,2); Katya Moniz(1,2); Noriko
4 Endo(3); Federica Armas(4,5); Mary Bushman(6); Peter R Chai(7,8); Claire
5 Duvallet(3); Timothy B Erickson(7,9,10); Katelyn Foppe(3); Newsha Ghaeli(3);
6 Xiaoqiong Gu(4,5); William P Hanage(6); Katherine H Huang(11); Wei Lin
7 Lee(4,5); Mariana Matus(3); Kyle A McElroy(3); Steven F Rhode(12); Stefan
8 Wuertz (5,13,14); Janelle Thompson(5,13,15); Eric J Alm(1,2,4,5,11)*

9

- 10 1: Department of Biological Engineering, Massachusetts Institute of Technology
11 2: Center for Microbiome Informatics and Therapeutics, Massachusetts Institute
12 of Technology
13 3: Biobot Analytics, Inc., Cambridge, MA
14 4: Singapore-MIT Alliance for Research and Technology, Antimicrobial
15 Resistance Interdisciplinary Research Group, Singapore
16 5: Campus for Research Excellence and Technological Enterprise (CREATE),
17 Singapore
18 6: Harvard T.H. Chan School of Public Health, Harvard University
19 7: Division of Medical Toxicology, Department of Emergency Medicine, Brigham
20 and Women’s Hospital, Harvard Medical School
21 8: The Fenway Institute, Fenway Health, Boston, MA
22 9: The Koch Institute for Integrated Cancer Research, Massachusetts Institute of
23 Technology
24 10: Harvard Humanitarian Initiative, Harvard University
25 11: Broad Institute of MIT and Harvard, Cambridge, MA, USA
26 12: Massachusetts Water Resources Authority, Boston, MA
27 13: Singapore Centre for Environmental Life Sciences Engineering, Nanyang
28 Technological University, Singapore
29 14: Civil and Environmental Engineering, Nanyang Technological University,
30 Singapore
31 15: Asian School of the Environment, Nanyang Technological University,
32 Singapore

33

34

35

36 † These authors contributed equally.

37 * Correspondence to EJA at ejalm@mit.edu

38 **Abstract**

39

40 Wastewater-based disease surveillance is a promising approach for monitoring
41 community outbreaks. Here we describe a nationwide campaign to monitor
42 SARS-CoV-2 in the wastewater of 159 counties in 40 U.S. states, covering 13%
43 of the U.S. population from February 18 to June 2, 2020. Out of 1,751 total
44 samples analyzed, 846 samples were positive for SARS-CoV-2 RNA, with overall
45 viral concentrations declining from April to May. Wastewater viral titers were
46 consistent with, and appeared to precede, clinical COVID-19 surveillance
47 indicators, including daily new cases. Wastewater surveillance had a high
48 detection rate (>80%) of SARS-CoV-2 when the daily incidence exceeded 13 per
49 100,000 people. Detection rates were positively associated with wastewater
50 treatment plant catchment size. To our knowledge, this work represents the
51 largest-scale wastewater-based SARS-CoV-2 monitoring campaign to date,
52 encompassing a wide diversity of wastewater treatment facilities and geographic
53 locations. Our findings demonstrate that a national wastewater-based approach
54 to disease surveillance may be feasible and effective.

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72 Introduction

73

74 COVID-19 was first reported in the United States on January 20, 2020, and
75 spread to all 50 states and the District of Columbia by mid-March^{1,2}. As of
76 February 1, 2021, over 26 million confirmed cases and over 440,000 deaths have
77 been reported in the U.S.². Establishing a national COVID-19 surveillance
78 system, like those for viral hepatitis and influenza, would be helpful for long-term
79 monitoring of SARS-CoV-2, allowing healthcare officials to recognize and
80 respond to new outbreaks efficiently and uniformly. However, COVID-19 poses
81 specific challenges to clinical surveillance systems, with its long infectious
82 incubation time (up to 14 days; median: 4-5 days) greatly increasing the risk of
83 viral transmission and infection among the population before clinical reporting,
84 contact tracing, and containment can occur^{3,4}. “Test and trace” systems were
85 rapidly overwhelmed in many countries early in the pandemic, and are often
86 ineffective once a disease reaches exponential community spread^{5,6}. The
87 emergence of more infectious variants may exacerbate this problem^{7,8}.

88

89 As a complementary approach to clinical disease surveillance, wastewater
90 monitoring can help detect the presence of pathogens like the coronavirus
91 SARS-CoV-2 across municipalities, and estimate disease incidence independent
92 of individual testing⁹⁻¹¹. Wastewater surveillance is less resource intensive than
93 large-scale clinical testing, making it an optimal tool for unobtrusive, long-term
94 monitoring as well as early identification of viral circulation in the population. Our
95 recent findings^{9,10} along with work from other groups have described reliable
96 detection of SARS-CoV-2 gene fragments in wastewater samples across the
97 world, including Australia¹², Brazil¹³, France, Netherlands¹⁴, Italy¹⁵, Spain¹⁶, and
98 the U.S.^{9,17}. Furthermore, longitudinal wastewater viral titers correlate with
99 clinically diagnosed new COVID-19 cases, and trends in wastewater precede
100 those in clinical reports by 4-10 days, suggesting that wastewater data could be
101 used as an early warning of impending outbreaks to define public health and
102 hospital planning¹⁰. The potential value of wastewater surveillance is gaining
103 recognition, with the Centers for Disease Control and Prevention and several
104 state and local health agencies initiating wastewater-based monitoring programs
105 to supplement their COVID-19 responses¹⁸.

106

107 We implemented a nationwide COVID-19 surveillance campaign to measure viral
108 concentrations of SARS-CoV-2 in the wastewater of 159 counties in 40 U.S.

109 states, from February to June 2020. We investigated the detection rate and
110 accuracy of wastewater surveillance of SARS-CoV-2 by comparing wastewater
111 data to clinically reported case counts from state and local health agencies. We
112 demonstrated the feasibility of utilizing wastewater surveillance as a supplement
113 to national SARS-CoV-2 clinical reporting data to understand important past,
114 current and future trends in viral dynamics.

115

116

117 **Results**

118

119 We collected and processed 1,751 wastewater samples from 353 unique
120 locations in 159 counties, in 40 U.S. states, from February 18 to June 2, 2020
121 (Fig. 1A). Of these samples, 1,687 were from locations that authorized the
122 disclosure of their metadata. Individual samples represented catchments serving
123 population sizes ranging from 65 to 5.3 million sewered individuals, with a
124 median size of 31,745 people (Fig. S1a). In total, these wastewater samples
125 covered 42.5 million people – approximately 13% of the U.S. population. To our
126 knowledge, this is the largest dataset reporting temporal tracking of SARS-CoV-2
127 in wastewater. Samples were processed as they were received in the lab and
128 quantified by real-time quantitative PCR (see Methods). 830 samples (49.1%)
129 were positive for SARS-CoV-2 gene fragments.

130

131 **Temporal dynamics of SARS-CoV-2 titers in wastewater samples from 159** 132 **counties in 40 states.**

133 For the month of March, we analyzed 86 wastewater samples from 25 counties
134 (42 individual catchments), in 10 states. We observed significant heterogeneity in
135 results at the county level. 44 of the 86 samples (51%) (from 12 counties in 8
136 states) were positive for SARS-CoV-2. In California, we found only 3 positive
137 samples from the 14 sampling locations (21%) in the 7 counties sampled in
138 March. On the other hand, we consistently detected SARS-CoV-2 in a
139 Massachusetts wastewater treatment plant (WWTP) starting on March 3 (93% of
140 samples), with viral titers increasing throughout the month (Fig. 1a). Positive
141 samples were also found in more than two counties in Colorado, Oregon, and
142 Texas.

143

144 In April, viral titers stopped increasing and became relatively stable for most
145 sampling locations (Fig. 1a and Fig. S1). Of the samples tested in April, 52.9%

146 (255 of 482) were SARS-CoV-2 positive: 173 samples from 44 counties had viral
147 titers between 10-100 copies per ml of wastewater; 78 samples from 24 counties
148 had viral titers higher than 100 copies per ml (Fig. 1a). We processed 1,092
149 samples from 154 counties in May. Of these, 69.5% (358/515) had positive
150 SARS-CoV-2 titers of 10-100 copies per ml of wastewater, and 18.8% (97/515)
151 had titers of >100 copies per ml (Fig. 1a). Analysis of April and May samples also
152 showed the heterogeneity in viral titers at the county and catchment levels (Fig.
153 S2).

154
155 We observed different dynamics in viral titers at the state level (Fig. 1a). Viral
156 titers in New Jersey (NJ) were high in March samples, but started to decrease
157 after April 8. Similar temporal dynamics were also observed in Michigan (MI), but
158 with a smaller magnitude. Comparatively, viral titers in Indiana (IN) and North
159 Carolina (NC) varied little over the sampling period (April and May). Nine states
160 (Virginia, Delaware, Michigan, Minnesota, Massachusetts, Oregon, New York,
161 Nebraska, and New Jersey) had titers higher than 100 copies per ml of
162 wastewater in April (Fig. 1b). This number dropped to two states (Maryland and
163 Minnesota) in May (Fig. 1c). Averaged across all states, the mean viral
164 concentration was significantly higher in April than in May (Fig. S1b). Together,
165 these data highlight that wastewater surveillance can be implemented to explore
166 viral transmission at different geographic and temporal scales.

167

168 **Wastewater viral dynamics are consistent with clinical COVID-19** 169 **surveillance indicators**

170 Next, we compared the wastewater viral titers with clinical surveillance data of
171 COVID-19 across the U.S. Aggregating the positive wastewater data and daily
172 new COVID-19 cases and new deaths by date, the mean viral titers increased
173 from early March and became relatively stable between late March to late April,
174 followed by a small downward trend until June 2 (Fig. 1d). This temporal profile
175 mirrors the trends of clinical new cases and deaths at the national level, and
176 precedes clinical data. Wastewater viral titers also reflected, and seemed to
177 precede, the rise and fall of hospitalization and intensive care unit admissions
178 (Fig. S3).

179

180 We also investigated the relationship between wastewater viral titers and daily
181 COVID-19 incidence rates. Viral concentration in the wastewater is determined
182 by the number of new infections, shedding rates from infected individuals, as well

183 as total influent flow at the wastewater treatment plant¹⁰, which is linearly
184 correlated with catchment population size (Fig. S4). A weak positive correlation
185 was found between the incidence of daily new cases at the county level, and the
186 wastewater viral titers at the catchment (wastewater treatment plant) level (Fig.
187 1e). We then compared total daily viral load for each catchment (viral
188 concentrations detected at wastewater treatment plant, multiplied by the plant's
189 daily influent flow rate), and the estimated number of new cases in that
190 catchment (county-level incidence rates multiplied by the catchment population).
191 A linear relationship was observed between the total viral load and catchment
192 size-normalized daily new cases (Fig. 1f), consistent with the hypothesis that
193 average shedding rates are similar across catchments.

194

195 **Estimation of detection rate and accuracy of wastewater surveillance**

196 Next, we investigated the detection rate of wastewater surveillance by comparing
197 wastewater titers to new clinical cases on the sampling day (Methods). Using the
198 reported daily incidence COVID-19 cases (i.e. daily new cases divided by the
199 county population size), we calculated the percentage of positive wastewater
200 samples for different incidence rates. Wastewater-based detections increased
201 exponentially with the clinical incidence rate, reaching an 80% rate of detection at
202 a clinical incidence of 13 cases per 100,000 people (Fig. 2a). For all positive
203 wastewater samples at the county level, the associated incidence rates of daily
204 new cases ranged from 0 – 149.6 cases per 100,000 people (median: 3.7 cases
205 per 100,000 people) (Fig. 2b). In other words, wastewater-based surveillance
206 was capable of detecting SARS-CoV-2 for one new reported case out of ~27,000
207 people. However, this new case rate does not consider unreported infections in
208 the population, which would lower the estimated detection limit.

209

210 To evaluate whether catchment size influences the probability of SARS-CoV-2
211 detection in wastewater samples, we analyzed the detection rate of positive
212 samples from counties with equal daily incidence. As shown in Fig. 2c, detection
213 rate is positively associated with the population size of wastewater treatment
214 plant catchments for the majority of samples. 100% detection rates were
215 disproportionately represented among samples with high incidence (>10 cases
216 per 100,000 people) and large population sizes (>100,000 people). This result is
217 consistent with our previous model simulations that the probability of SARS-CoV-
218 2 detection in the wastewater increases with population size in communities with
219 equal incidence¹⁰.

220

221 To evaluate the detection accuracy of wastewater surveillance, we compared the
222 wastewater results with reported daily new clinical cases. For all 1,687 samples
223 for which we had access to metadata, 1,057 (62.7%) exhibited results consistent
224 with the geographically associated clinical data, meaning that SARS-CoV-2 was
225 detected in the wastewater in areas with new clinical cases (759 samples,
226 “W1.C1”), and not detected in areas where no new cases were reported (298
227 samples, “W0.C0”) (Fig. 2d). Of the remaining 630 samples, 559 had clinical
228 cases but SARS-CoV-2 was not detected in the wastewater (“W0.C1”). Of these,
229 67.4% were from counties with incidence rates below the median of all
230 wastewater samples (3.7 cases per 100,000). We also compared the pepper
231 mild mottle virus levels (PMMoV), a stable and persistent indicator of fecal
232 concentration in wastewater^{9,19,20}, and found that PMMoV copies in the W0.C1
233 samples were slightly but significantly lower than in other samples (Fig. S5a),
234 suggesting that sample dilution and low incidence rates may have contributed to
235 wastewater non-detections. Finally, there were 71 samples (“W1.C0”) for which
236 SARS-CoV-2 was detected, but there were no new clinical cases reported (Fig.
237 2d). Most of these samples’ viral titers ranged from 10 to 272 copies/ml (Fig.
238 S5b). Comparison of the wastewater data against the 7-day averages of new
239 clinical cases did not yield substantially different results (Fig. S5c-d).

240

241

242 **Discussion**

243

244 In this study, we tested and quantified SARS-CoV-2 genome copies in 1,751
245 wastewater samples, collected from 159 U.S. counties in 40 states, using RT-
246 qPCR. This nationwide campaign covered approximately 13% of the U.S.
247 population and demonstrated that widespread wastewater surveillance is feasible
248 and useful across various catchment sizes. Overall, viral titers increased starting
249 in early March, and became relatively stable until April, followed by a small
250 decrease in May. Thirty-eight out of 40 states we sampled issued stay-at-home
251 orders or advisories between March 19 and April 7, and all 40 sampled states put
252 statewide restrictions on activity in place between March 10 and April 6
253 (<https://www.usatoday.com/storytelling/coronavirus-reopening-america-map/>).
254 These social distancing guidelines may have contributed to the relatively stable
255 viral titers in April and downward trend in May.

256

257 Wastewater surveillance of SARS-CoV-2 has been widely employed in the U.S.
258 and other countries, however, the detection rate and limit have been unclear. Our
259 spatiotemporal wastewater dataset enabled us to address this question.
260 Assuming an equal incidence rate throughout the county, our analysis showed
261 that wastewater-based SARS-CoV-2 monitoring has a high chance (> 80%) of
262 detecting the viral RNA when the incidence of daily new cases exceeds 13 cases
263 per 100,000 people. Considering only positive wastewater samples, the median
264 detection limit becomes 1 case per ~27,000 people. Our analysis is based on
265 case reports from public health agencies, which are likely underestimates of true
266 infection rates.

267
268 This study has several limitations. First, all surveillance data are limited by
269 sampling regimes which could introduce bias through either the frequency of
270 sampling or the specific locations sampled, which is true for both wastewater
271 surveillance and case counts reported by public health authorities. A more
272 unbiased sampling strategy including representative locations and appropriate
273 time intervals would improve our estimate about the viral transmission in the
274 population. Second, sample numbers were biased by month, 5.1% samples were
275 from March and 55.5% samples were from May, thus our analysis may be
276 affected by the low sampling resolution during the early stage of the pandemic.
277 Third, all the samples were collected by each wastewater treatment plant, and
278 mailed to us for analysis, and thus variation in sample collection and transport
279 conditions may have further influenced data comparability. National
280 implementation of a wastewater-based detection system would require standard
281 operating procedures for sample collection, local processing, and analysis.

282
283 Here, we reported wastewater levels of SARS-CoV-2 in 159 counties in 40 U.S.
284 states, from mid-February to early June 2020, and showed that wastewater data
285 largely parallels and precedes clinical and epidemiological indicators of COVID-
286 19 pandemics. Across the country, wastewater surveillance had a high SARS-
287 CoV-2 detection rate (>80%) when the local daily incidence exceeded 13
288 reported cases per 100,000 people. The detection rate was positively associated
289 with catchment population size. To our knowledge, this is the largest nationwide
290 investigation of SARS-CoV-2 in wastewater samples in the U.S. during the
291 COVID-19 pandemic, with samples from 353 catchments representing 13% of
292 the U.S. population. This noninvasive and cost-effective approach could be
293 employed as a complementary tool for long-term monitoring of SARS-CoV-2 - as

294 well as other infectious diseases and other health-relevant biomarkers - across
295 the United States.

296

297

298 **Methods**

299

300 **Sample collection and viral inactivation.** We initiated a national call for
301 wastewater samples to quantify SARS-CoV-2 viral load in wastewater catchment
302 areas from mid-February to early June 2020. Eligible sites included public works
303 and wastewater authorities across the continental United States. Samples were
304 collected by each wastewater treatment facility on a voluntary basis. Raw
305 wastewater samples were collected from the wastewater treatment plants or
306 catchments in 40 U.S. states and stored at 4C before being mailed to the
307 laboratory for analysis. Samples were processed using the method as previously
308 described^{9,10}. Briefly, samples were first inactivated by ultraviolet light for 20 mins
309 and heat treatment in a 60C water bath for 90 mins. Pasteurized samples were
310 vacuum filtered with a 0.22-um polyethersulfone membrane to remove cell debris
311 and solid materials. Supernatant was stored at 4C, and used for the viral
312 enrichment.

313

314 **Viral precipitation, RNA extraction, reverse transcription and quantitative**
315 **PCR (RT-qPCR).** We processed the samples starting from viral enrichment to
316 quantitative PCR with two comparable methods as previously described¹⁰. 60
317 samples from deer island wastewater treatment plant were processed with both
318 two methods, and no significant difference between viral titers was observed¹⁰.
319 1023 samples were processed with Method I, and 729 samples were processed
320 with Method II. Briefly, viral particles in 40-ml filtrate were precipitated with
321 polyethylene glycol 8000 (10% w/v, Millipore sigma) and NaCl (0.3M, Millipore
322 sigma) in Method I. Viral pellet was resuspended in 1.5 mL Trizol reagent (Cat#
323 15596026, Thermo Fisher Scientific) for RNA extraction. cDNA was synthesized
324 by reverse transcription (RT) based on the manufacturer's protocol (M0368, New
325 England Biosciences), followed by real-time PCR with the TaqMan® Fast
326 Advanced Master Mix and U.S. CDC N1, N2 primer/probes. The qPCR reaction
327 was carried out for 48 cycles using Bio-Rad CFX96 Real-Time PCR Detection
328 System with following program: polymerase activation (95°C for 2 min), PCR (48
329 cycles, denature at 95°C for 1 s, and anneal/extend at 55°C for 30 s).

330

331 15 ml of filtrate in Method II were first concentrated with 10 kDa Amicon Ultra
332 Centrifugal Filter (Sigma, Cat# UFC9010) to 150 ~ 200 ul, which is further lysed
333 with 600 ul AVL buffer (Qiagen, Cat# 19073) for RNA extraction (Qiagen RNeasy
334 kit, Cat# 74182). The eluted RNA was used for one-step RT-PCR with TaqMan™
335 Fast Virus 1-Step Master Mix (Thermofisher, Cat# 4444436), based on the
336 following protocol: 50°C 10 mins for reverse transcription, 95°C 20 s for RT
337 inactivation and initial denaturation, and 48 cycles of denature (95°C 1 s) and
338 anneal/extend (55°C 30 s).

339

340 Ct values for N1 or N2 primer sets were first converted to viral gene copies in the
341 cDNA sample (copies per ul of cDNA) based on the standard curves established
342 with the positive control plasmid (Method I) or Twist SARS-CoV-2 RNA (Method
343 II) (10). The concentration was further converted to viral gene copies per
344 microliter of the wastewater sample by multiplying the dilution factor. For Method
345 I, the dilution factor is: the volume of total cDNA * the total volume of RNA / (the
346 volume of RNA used for reverse transcription * the starting volume of filtered
347 wastewater sample). For Method II, the dilution factor is: The total volume of
348 RNA / the starting volume of filtered wastewater sample). Two or three replicates
349 were performed for each primer set, averaged within each primer set and then
350 across primers to derive the concentration values. We also measured PMMoV
351 concentration in the sample as an internal reference for wastewater samples. We
352 performed two technical replicates for each sample and converted the mean Ct
353 values to relative concentrations of viral particles based on the standard curve⁹
354 and sample's dilution factor.

355

356 **Clinical data collection and detection rate analysis.** County-level clinical data
357 including cumulative COVID-19 cases and deaths were downloaded from
358 USAFACTS ([https://usafacts.org/visualizations/coronavirus-covid-19-spread-](https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/)
359 [map/](https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/)). Daily new cases or deaths were generated through using the cumulative
360 data on one day to subtract the data before that day. We compared wastewater
361 viral titers to clinical data reported for the day on which the sample was obtained.
362 For the detection accuracy analysis in Fig. S5c-d, we also compared the
363 wastewater data against the 7-day moving average of new clinical cases (current
364 day + 6 preceding days / 7). Hospitalizations and positive rates of testing for each
365 state were downloaded from The COVID Tracking Project
366 (<https://covidtracking.com/>).

367

368 Incidence rate of daily new cases was calculated using reported daily new cases
369 in the county divided by the county population size. In Fig. 2a, we computed the
370 detection rates, percentage of positive wastewater samples, for a constant
371 interval (0.2 cases per 100,000 people) of daily incidence, starting from 0 to
372 149.6 cases per 100,000 people (maximum daily incidence). The results were
373 fitted using an exponential decay function with formula: $y \sim k_1 + V_{max} * (k_2 - \exp(-x$
374 $/ \tau))$, starting from $V_{max} = 10$, $\tau = 1$, and $k_1 = 0.2$, $k_2 = 1.15$. To estimate the
375 distribution of daily incidence for all the positive samples, we first aggregated
376 wastewater viral titers for each county, since clinical cases were reported at the
377 county level. Then we selected the positive samples and plotted the histogram
378 and Kernel density estimation of the distribution of daily incidence (Fig. 2b). In
379 Fig. 2c, we investigated the relationship between detection rate of positive
380 wastewater samples and the catchment population size. We first separated the
381 samples based on four different daily incidences (0, (0,2), [2,10), and [10,100),
382 per 100,000 people) in the county where the sample was obtained. For each
383 daily incidence, we computed the detection rate for a constant interval of
384 population size, i.e. the maximum minus minimum of population size, and divided
385 by the number of bins ($n=200$). All the analysis was done with R (3.5.0).

386

387

388 **Acknowledgments**

389 We thank the management and sampling teams at all the wastewater treatment
390 facilities who worked with us in providing the samples for analysis. We thank
391 Penny Chisholm (MIT) and Allison Coe (MIT) for access to equipment and other
392 supplies, Shandrina Burns (MIT) for logistical support. Finally, we express our
393 deep gratitude to all healthcare professionals and first-line responders who have
394 been caring for patients with COVID-19.

395

396 This work was supported by the Center for Microbiome Informatics and
397 Therapeutics and Intra-CREATE Thematic Grant (Cities) grant NRF2019-
398 THE001-0003a to JT and EJA; National Institute on Drug Abuse of the National
399 Institutes of Health award numbers K23DA044874; and R44DA051106 to MM
400 and PRC, Hans and Mavis Psychosocial Foundation funding, and e-ink
401 corporation funding to PRC; funding from the Morris-Singer Foundation and NIH
402 award R01AI106786 to WPH; funds from the Massachusetts Consortium on
403 Pathogen Readiness and China Evergrande Group to TBE, PRC, MM, and EJA;
404 funding from the Singapore Ministry of Education and National Research

405 Foundation through an RCE award to Singapore Centre for Environmental Life
406 Sciences Engineering (SCELSE) to SW and JT. The content is solely the
407 responsibility of the authors and does not necessarily represent the official views
408 of the funding institutions.

409

410

411 **Competing Interests**

412 MM and NG are cofounders of Biobot Analytics. EJA is advisor to Biobot
413 Analytics. CD, KAM, KF, and NE are employees at Biobot Analytics, and all
414 these authors hold shares in the company.

415

416

417 **Data Availability**

418 The data presented in the figures, and the code for the analysis, and that support
419 the other findings of this study are available from the corresponding author on
420 reasonable request.

421


422

423 **References**

- 424 1. Holshue, M. L. *et al.* First Case of 2019 Novel Coronavirus in the United
425 States. *New England Journal of Medicine* **382**, 929–936 (2020).
- 426 2. Johns Hopkins University Center for Systems Science and Engineering.
427 COVID-19 Map - Johns Hopkins Coronavirus Resource Center.
428 <https://coronavirus.jhu.edu/map.html> (2020).
- 429 3. Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019
430 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and
431 Application. *Ann Intern Med* (2020) doi:10.7326/M20-0504.
- 432 4. CDC. Coronavirus Disease 2019 (COVID-19)-COVID-19 Pandemic Planning
433 Scenarios. *Centers for Disease Control and Prevention*
434 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>
435 (2020).
- 436 5. Kretzschmar, M. E. *et al.* Impact of delays on effectiveness of contact tracing
437 strategies for COVID-19: a modelling study. *The Lancet Public Health* **5**,
438 e452–e459 (2020).

- 439 6. Contreras, S. *et al.* The challenges of containing SARS-CoV-2 via test-trace-
440 and-isolate. *Nature Communications* **12**, 378 (2021).
- 441 7. Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L. & Cevik, M.
442 Public health actions to control new SARS-CoV-2 variants. *Cell* (2021)
443 doi:10.1016/j.cell.2021.01.044.
- 444 8. Galloway, S. E. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United
445 States, December 29, 2020–January 12, 2021. *MMWR Morb Mortal Wkly*
446 *Rep* **70**, (2021).
- 447 9. Wu, F. *et al.* SARS-CoV-2 titers in wastewater are higher than expected from
448 clinically confirmed cases. *mSystems* **5**, 2020.04.05.20051540 (2020).
- 449 10. Wu, F. *et al.* SARS-CoV-2 titers in wastewater foreshadow dynamics and
450 clinical presentation of new COVID-19 cases. *medRxiv* (2020)
451 doi:10.1101/2020.06.15.20117747.
- 452 11. Orive, G., Lertxundi, U. & Barcelo, D. Early SARS-CoV-2 outbreak detection
453 by sewage-based epidemiology. *Science of The Total Environment* **732**,
454 139298 (2020).
- 455 12. Ahmed, W. *et al.* First confirmed detection of SARS-CoV-2 in untreated
456 wastewater in Australia: A proof of concept for the wastewater surveillance of
457 COVID-19 in the community. *Science of The Total Environment* **728**, 138764
458 (2020).
- 459 13. Prado, T. *et al.* Preliminary results of SARS-CoV-2 detection in sewerage
460 system in Niterói municipality, Rio de Janeiro, Brazil. *Mem Inst Oswaldo Cruz*
461 **115**, (2020).
- 462 14. Medema, G., Heijnen, L., Elsinga, G., Italiaander, R. & Brouwer, A. Presence
463 of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported
464 COVID-19 Prevalence in the Early Stage of the Epidemic in The Netherlands.
465 *Environ. Sci. Technol. Lett.* (2020) doi:10.1021/acs.estlett.0c00357.
- 466 15. La Rosa, G. *et al.* First detection of SARS-CoV-2 in untreated wastewaters in
467 Italy. *Science of The Total Environment* **736**, 139652 (2020).

- 468 16. Chavarria-Miró, G. *et al.* Sentinel surveillance of SARS-CoV-2 in wastewater
469 anticipates the occurrence of COVID-19 cases. *medRxiv*
470 2020.06.13.20129627 (2020) doi:10.1101/2020.06.13.20129627.
- 471 17. Peccia, J. *et al.* Measurement of SARS-CoV-2 RNA in wastewater tracks
472 community infection dynamics. *Nature Biotechnology* 1–4 (2020)
473 doi:10.1038/s41587-020-0684-z.
- 474 18. CDC. National Wastewater Surveillance System. *Centers for Disease Control*
475 *and Prevention* [https://www.cdc.gov/coronavirus/2019-ncov/cases-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/wastewater-surveillance.html)
476 [updates/wastewater-surveillance.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/wastewater-surveillance.html) (2020).
- 477 19. Kitajima, M., Sassi, H. P. & Torrey, J. R. Pepper mild mottle virus as a water
478 quality indicator. *npj Clean Water* **1**, 1–9 (2018).
- 479 20. Kitajima, M., Iker, B. C., Pepper, I. L. & Gerba, C. P. Relative abundance and
480 treatment reduction of viruses during wastewater treatment processes —
481 Identification of potential viral indicators. *Science of The Total Environment*
482 **488–489**, 290–296 (2014).
- 483
- 484



486

487 **Fig. 1. SARS-CoV-2 RNA gene copies in wastewater samples from 40 U.S.**
 488 **states.** (a) Temporal profile of SARS-CoV-2 viral RNA gene copies (viral titers) in
 489 the wastewater samples collected from February 18 to June 2, 2020. Each grey
 490 point represents a sample, and the grey line connects samples collected from the

491 same catchment. Temporal dynamics of mean viral titers from five U.S. states
492 are highlighted. Negative samples (SARS-CoV-2 not detected) were assigned to
493 '0'. (b-c) Mean viral titers for each state in April (b) and May (c). All the samples
494 in April or May were aggregated by state. NA: data is not available for the state.
495 (d) Temporal dynamics for the mean viral titers, daily new COVID-19 cases, and
496 new deaths. Viral concentrations (red line) from positive wastewater samples
497 were aggregated by date, and new cases (green line) and COVID-19-related new
498 deaths (blue line) from the wastewater sample originated counties were also
499 aggregated and averaged by date. (e) Association between viral titers in
500 wastewater samples and the reported daily incidence rate in each sampled
501 counties. (f) Association between the total viral load and estimated new cases in
502 each of the catchment areas. Total viral load of SARS-CoV-2 in wastewater
503 (copies/day) was calculated by multiplying SARS-CoV-2 concentration
504 (copies/ml) by the daily average influent flow (ml/day) reported by the WWTP.
505 Population weighted new cases was calculated as county new cases * catchment
506 population / county population.

507

508

509


510

511

512

513

514



51!
516
517
518
519
520
521
522
523
524
525
526
527
528
529

Fig. 2. Detection rate and accuracy of wastewater-based SARS-CoV-2 surveillance.

(a) Detection rate for varying daily incidence of COVID-19 cases. Each dot represents the percentage of positive wastewater samples for a constant incidence interval, and the red line is the nonlinear fit. The vertical dashed line indicates the incidence ($x = 13$) above which the fitted detection rate exceeds 0.8. (b) The distribution of daily incidence for the counties where SARS-CoV-2 was detected in the wastewater samples. Blue line is the Kernel density estimation of the daily incidence's distribution. The median of the incidence is 3.7 cases per 100,000 people). (c) Relationship between the detection rate of positive wastewater samples from a given treatment plant and the population size served by that plant. Detection rate is binned by population size, and colored by the incidence intervals. (d) Detection status for all the samples ($n = 1,687$).

530 Wx.Cx (x = 1 or 0): consistent results between wastewater data and clinical
531 reports. W1.C1: SARS-CoV-2 detected in Wastewater (W1) and new Clinical
532 cases reported (C1); W0.C0: no Wastewater detection (W0) and no new Clinical
533 cases reported (C0); W0.C1: no Wastewater detection (W0) but new Clinical
534 cases reported (C1); W1.C0: Wastewater detection (W1) but no new Clinical
535 cases reported (C0).

536

537


538

539

540 Supplemental figures

541

542



543

544

545 **Fig. S1.** Distribution of the wastewater treatment plant serving population size,
546 and viral titers in positive wastewater samples by month. (a) Histogram of
547 population sizes served by the sampled wastewater treatment plants. The
548 median served population size is 31,745. (b) Viral titers in positive wastewater
549 samples by month. The box represents the interquartile range of viral titers for
550 each month, the horizontal line inside the box is the median. Significant
551 difference was found between the mean viral titers in April and May (Welch's t-
552 test, p-value = 0.025).

553


554

555
556
557
558
559
560
561



563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578

Fig. S2. Temporal SARS-CoV-2 titers at the county level and catchment level. (a) Temporal viral titers in 12 representative counties. Each dot is a sample, and colored by the sampling catchments in the county. Red lines represent the daily new cases in the corresponding counties during the sampling period. (b) Temporal viral titers for samples collected in six different locations in the New Castle County of Delaware. Red lines represent the weighted daily new cases (daily new cases in the county multiplying the catchment served population size and divided by the county population size) during the sampling period.




579

580 **Fig. S3.** Wastewater viral titers (top) and clinical COVID-19 surveillance
581 indicators including hospitalization and intensive care unit admissions (middle),
582 and the testing positive rates (bottom) from February to June. Positive
583 wastewater data from all the sampling locations were aggregated by date using
584 the mean function. Clinical data from the 40 sampled states were aggregated in
585 the same way.

586


587

588



589
590
591
592
593
594
595

Fig. S4. Daily average influent flow at the wastewater treatment plant is correlated with catchment population size.



596
597

598 **Fig. S5.** PMMoV concentrations in wastewater samples, and detection status
599 with 7-day averages of new COVID-19 cases. (a) PMMoV concentrations in the
600 Wx.Cx (x = 0 or 1), W0.C1, and W1.C0 groups. W1.C1: SARS-CoV-2 detected in
601 Wastewater and new Clinical cases reported; W0.C0: no Wastewater detection
602 and no new Clinical cases reported; W0.C1: no Wastewater detection but new
603 Clinical cases reported; W1.C0: Wastewater detection but no new Clinical cases
604 reported. Significant differences of PMMoV concentrations were found between
605 W0.C1 and Wx.Cx or W1.C0 groups (Welch's t-test, and symbol *: p-value <
606 0.05; ***: p-value < 0.001). (b) Viral titers and the served population size for the
607 W1.C0 samples. Most of these samples were from catchments serving 10,000 ~
608 100,000 population, with viral titers ranging from 10 to 100 copies per ml of
609 wastewater. (c-d) Detection status for wastewater data against 7-day averages of
610 new clinical cases (c), and PMMoV concentrations in the Wx.Cx, W0.C1, and
611 W1.C0 groups (d). Significant difference was found between Wx.Cx and W0.C1
612 groups (Welch's t-test, and symbol ***: p-value < 0.001).